Gianluigi Marasi

Sexual activity in hypertensive men treated with valsartan or carvedilol : A crossover study

The aim of this study was to compare the effect of antihypertensive treatment with valsartan or cavedilol on sexual activity in hypertensive men who were never treated for hypertension. A total of 160 newly diagnosed hypertensive men (diastolic blood pressure [DBP] > or = 95 mm Hg and < 110 mm Hg), aged 40 to 49 years, all married and without any previous sexual disfunction, were enrolled. After a 4-week placebo period, the patients were divided into two groups: a) 120 patients were randomized to receive carvedilol 50 mg once daily or valsartan 80 mg once daily for 16 weeks according to a double-blind, cross-over design; after another 4-week placebo period, patients were crossed over to the alternative regimen for a further 16 weeks; b) 40 patients were treated with placebo according to a single-blind design for 16 weeks. At the screening visit and every 4 weeks thereafter, blood pressure (BP) was evaluated and patients were interviewed by a questionnaire about their sexual activity. Blood pressure was significantly lowered by both treatments, with a 48% of normalization with valsartan and 45% with carvedilol. During the first month of therapy, sexual activity (assessed as number of sexual intercourse episodes per month) declined with both drugs as compared with baseline, although the decrease was statistically significant in the carvedilol (from 8.2 to 4.4 sexual intercourse episodes, P < .01) but not in the valsartan-treated patients (from 8.3 to 6.6 sexual intercourse episodes, not significant). Ongoing with the treatment the sexual activity further worsened with carvedilol (3.7 sexual intercourse episodes per month) while fully recovered and also improved with valsartan (10.2 sexual intercourse episodes per month). The results were confirmed by the cross-over. Erectile dysfunction was a complaint of 15 patients with carvedilol (13.5%), one patient with valsartan (0.9%), and one patient in the placebo group. These findings suggest that carvedilol induces a chronic worsening of sexual activity, whereas valsartan not only does not significantly worsen sexual activity but may even improve it.

Sexual activity and plasma testosterone levels in hypertensive males

The aim of this study was to compare sexual activity and plasma testosterone levels of hypertensive men with those of healthy normotensive controls. We investigated 110 newly diagnosed, never treated hypertensive (blood pressure [BP] > or = 140/95 mm Hg) men and 110 healthy normotensive (diastolic BP <90 mm Hg) men. All of them were aged 40 to 49 years, married, without any previous sexual dysfunction, nondiabetic, nonobese (body mass index <28 kg/m2), nonsmoking, and not taking any drug. All subjects were evaluated in the morning after an overnight fast. Clinical evaluation included BP, body weight, and height measurements, determination of testosterone, and an interview about sexual activity, assessed as number of sexual intercourse episodes per month. Hypertensive men presented a 25% reduction in sexual activity as compared to normotensive men (5.9 +/- 2.6 v 7.9 +/- 2.5 sexual intercourse episodes per month, respectively, P < .01) and a 12% reduction in testosterone levels (510.6 +/- 151.9 ng/dL v 578.6 +/- 146.8 ng/dL, P < .01). In both normotensive and hypertensive men Pearsons correlation analysis showed a significant positive correlation between testosterone levels and sexual activity and a significant negative correlation between testosterone and age and between testosterone and BP values. Multiple regression analysis confirmed a significant inverse relationship between testosterone and age in normotensive men, whereas only a nonsignificant trend was found in the hypertensive ones. In addition, a significant inverse correlation between testosterone and BP levels was confirmed in hypertensive men limited to systolic BP, whereas a nonsignificant trend was observed in the normotensive controls. In conclusion, these findings suggest a relationship between essential hypertension and impaired testosterone levels in men. The elucidation of the nature of such a relationship and its physiologic and clinical significance needs further investigation.

Transient but not sustained blood pressure increments by occupational noise. An ambulatory blood pressure measurement study.

Objective Studies on the effects of chronic exposure to industrial noise on clinic blood pressure (BP) at rest have yielded inconsistent results. The aim of this study was to evaluate the effect of occupational noise exposure on ambulatory blood pressure (ABP) in normotensive subjects. Methods We studied 476 normotensive workers, aged 20–50 years (systolic blood pressure (SBP) < 140, diastolic blood pressure (DBP) < 90), at a metallurgical factory; 238 were exposed to high levels of noise (> 85 dB), while 238 were not exposed (< 80 dB). Clinical evaluation included measurements of casual BP (by standard mercury sphygmomanometer, Korotkoff sound phase I and V) and heart rate (HR) (by pulse palpation), body height and weight. All subjects underwent a 24 h non-invasive ABP monitoring (by SpaceLabs 90207 recorder; SpaceLabs, Redmond, Washington, USA) twice within 14 days: one during a normal working day and one during a non-working day. Measurements were performed every 15 min. Computed analysis of individual recordings provided average SBP, DBP and HR values for 24 h, daytime working hours (0800–1700 h), daytime non-working hours (1700–2300 h) and night-time (2300–0800 h). Results No significant difference in clinic SBP, DBP and HR was observed between exposed and non-exposed subjects. Results obtained by ABP monitoring showed in the exposed workers: (a) a higher SBP (by a mean of 6 mmHg, P < 0.0001 versus controls) and DBP (by a mean of 3 mmHg, P < 0.0001) during the time of exposure and the following 2 or 3 h, whereas no difference between the two groups was found during the non-working day; (b) an increase in HR, which was present not only during the time of exposure to noise (+3.7 beats-per-minute (bpm), P < 0.0001 versus controls), but also during the non-working hours (+2.8 bpm, P < 0.001) and during the day-time hours of the non-working day (+2.8 bpm, P < 0.003); (c) a significant increase in BP variability throughout the working day. Conclusions These findings suggest that in normotensive subjects below the age of 50 years, chronic exposure to occupational noise is associated with a transient increase in BP, which is not reflected in a sustained BP elevation. The possible role of repeated BP and HR fluctuations due to frequent and prolonged exposure to noise in accounting for the higher prevalence of hypertension reported in noise-exposed workers above age 50 years, requires longitudinal studies to be clarified.

Occupational noise exposure and blood pressure.

Objective To investigate the relationship between occupational noise exposure and blood pressure Methods We studied 8811 workers at a metallurgical factory, who were exposed to different levels of noise at the worksite: ≤80 dB for 8078 workers and >80 dB for 733 workers. A clinical examination, including measurements of blood pressure (by mercury sphygmomanometer, Korotkoff phases I and V), heart rate (by pulse palpation), body weight and height, was performed. The subjects were stratified into four age groups (18–30, 31–40, 41–50 and >50 years) and into two body mass index groups: normal weight (≤25 kg/m2) and overweight (>25 kg/m2). In order to eliminate possible confounding factors and statistical bias, a retrospective case versus control analysis was also carried out Results The epidemiologic approach showed that the systolic blood pressure (SBP) but neither the diastolic blood pressure (DBP) nor the heart rate values were statistically higher in the group who were exposed to noise levels of >80dB, although the difference could be considered clinically relevant only in the older age group. The prevalence of hypertension (according to World Health Organization criteria) was higher among the workers who were exposed to the higher levels of noise. Stratification for body mass index confirmed the existence of a higher prevalence of hypertension in the exposed group. The results from the case versus control analysis indicated that both the SBP and the DBP levels in the exposed group were significantly higher than those in the reference group, and confirmed the existence of a higher prevalence of hypertension in the exposed group Conclusions The present data suggest that occupational exposure to noise levels exceeding 80dB may lead to a higher prevalence of hypertension and to increased blood pressure values, although the results appear quantitatively different according to the approach that is taken to the problem (i.e. the epidemiologic or the case versus control approach)

Cigarette Smoking and Blood Pressure in a Worker Population: A Cross-Sectional Study

Background Cigarette smoking has been reported to cause an acute increase in blood pressure (BP). Nevertheless, many epidemiological studies have found lower average BP values in smokers than in non-smokers. The aim of this study was to evaluate the possible existence of a systematic difference in BP values between smokers and non-smokers in a worker population. Methods We studied 7109 employees of a metallurgical factory, all men, aged 18–60 years, 3237 non-smokers and 3872 smokers; of the latter, 816 smoked less than 10 cigarettes per day (light smokers), the others smoked 10 or more cigarettes per day. Clinical examination included measures of resting BP (by mercury sphygmomanometer), heart rate (HR) (by pulse palpation), body weight and height. Data were adjusted for age and body mass index (BMI). Four age groups (18–30, >30, >40 and >50 years) and 3 BMI groups (<25, 25–30, >30) were considered. Results In smokers, the adjusted values of systolic BP (SBP) and HR (127.72 mmHg and 75.16 beats/min, respectively) were slightly but significantly higher than in non-smokers (127.1 mmHg, P <0.05 and 72.64 beats/min, P < 0.001), whereas diastolic BP (DBP) was significantly lower (83.37 versus 84.31 mmHg, P < 0.001). Considering the amount of cigarettes smoked, the mean BP values of light smokers were not significantly different from those of subjects smoking 10 or more cigarettes per day, whereas HR mean values were significantly higher in the latter. The prevalence of hypertension (WHO criteria) was similar in smokers and non-smokers in each age group. Conclusions Our data showed slightly but statistically higher SBP and HR, and lower DBP mean values in smokers than in non-smokers; however, the differences in BP, although significant from the statistical point of view, were not of actual clinical significance.

Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension

Abstract Background: Reduced fibrinolysis due to increased concentrations of plasminogen activator inhibitor type 1 (PAI-1), the primary physiological inhibitor of endogenous fibrinolysis, is associated with an increased risk for cardiovascular events. Objective: This study was undertaken to compare the effects of 4 angiotensin II (AII)-receptor antagonists with different pharmacokinetic properties—losartan, valsartan, irbesartan, and candesartan—on levels of PAI-1 antigen in postmenopausal women with hypertension. Methods: Postmenopausal women aged 51 to 60 years with mild to moderate hypertension (diastolic blood pressure [DBP] > 90 mm Hg and ≤105 mm Hg) who were not taking any hormone replacement therapy were studied. Patients with diabetes or obesity and patients who smoked were excluded. After a 2-week placebo washout period, patients were assigned to receive losartan 50 mg, valsartan 80 mg, irbesartan 150 mg, candesartan 8 mg, or placebo for 12 weeks according to a double-blind, randomized, parallel-group design, with a titration for nonresponders after 6 weeks. At the end of the placebo period and 6 and 12 weeks after active treatment, blood pressure, PAI-1 antigen levels, heart rate, and body mass index were measured. Results: A total of 156 patients were randomized to receive losartan (n = 31), valsartan (n = 32), irbesartan (n = 31), candesartan (n = 32), or placebo (n = 30); of these, 140 completed the study. All 4 active treatments significantly reduced DBP and systolic blood pressure, with no significant differences in efficacy between groups. Plasma PAI-1 levels decreased slightly after treatment with losartan (−0.9%) and valsartan (−3.8%) and increased slightly with irbesartan (+10.1%), but these values were not significantly different from placebo. In contrast, candesartan significantly increased PAI-1 values by 33.3% ( P Conclusions: These findings suggest that, despite a comparable antihypertensive efficacy, candesartan differs from the other AII-receptor antagonists studied in that it significantly increases PAI-1 antigen levels. This might be related to its specific pharmacologic characteristics, particularly its insurmountable antagonism of the AII AT1 receptor.

A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system

Abstract Objective The objectives of this study were to assess the effects of 4 angiotensin II-receptor antagonists—losartan, valsartan, irbesartan, and candesartan—on blood pressure (BP) and plasma active renin (PAR), and to determine whether equipotent antihypertensive doses of these drugs produce different degrees of reactive activation of the renin-angiotensin system (RAS). Methods This double-blind, crossover study included 40 patients with mild to moderate hypertension (diastolic BP [DBP] >90 and 90 mm Hg or a reduction in DBP of Results In the group treated with standard initial doses of the 4 drugs, BP was consistently lower than during the placebo period; however, the decrease in BP was greater after treatment with valsartan 80 mg (−13.8/−9.8 nun Hg) and irbesartan 150 mg (−14.1/−9.9 mm Hg) than after treatment with losartan 50 mg (−9.9/−6.9 mm Hg; P P Conclusions Losartan, valsartan, irbesartan, and candesartan are not equipotent in lowering BP when used at the initial doses recommended by their respective manufacturers. At equipotent doses, there appears to be no correlation between the antihypertensive efficacy of these drugs and the degree of reactive activation of the RAS.

Associations between Plasma Fibrinogen Levels and Cardiovascular Risk Factors in Hypertensive Men

Background: Fibrinogen levels are reported to be elevated in hypertensive patients and tend to cluster with nearly all other established cardiovascular risk factors. The aim of this study was to evaluate the relationship between plasma fibrinogen and a number of other cardiovascular risk factors in patients with essential hypertension. Methods: We studied 118 men with essential hypertension, aged 18–65 years. The clinical evaluation included measurements of blood pressure (mercury sphygmomanometer, Korotkoff I and V), levels of plasma fibrinogen, total cholesterol, high-density-lipoprotein (HDL) cholesterol, triglycerides and blood glucose and the ratio of total-cholesterol to HDL-cholesterol levels; a detailed history of medical and personal habits was also recorded. Results: As expected, plasma fibrinogen levels were significantly higher in smokers than in non-smokers, with the number of cigarettes smoked correlating postively with the fibrinogen level. Patients with a total-cholesterol level in excess of 220mg/dl had significantly higher fibrinogen levels, and both univariate and multivariate analyses showed total-cholesterol and fibrinogen levels to be positively correlated. A weaker but significant relationship was noted between the fibrinogen level and triglyceride levels (P = 0.001 7) and between the fibrinogen level and the ratio of total-cholesterol to HDL-cholesterol levels (P = 0.0006). Fibrinogen levels were not significantly associated with either systolic or diastolic blood pressures. Conclusion: A family history of hypertension appears to potentiate the tendency of fibrinogen to cluster with other cardiovascular risk factors in hypertensive patients.

The epidemiology of resting heart rate in a male working population: association with blood pressure, age, smoking habits and other cardiovascular risk factors.

Aim To evaluate heart rate and its relationship with some established cardiovascular risk factors in normotensive and hypertensive individuals. Methods We studied 8811 men, 696 with essential hypertension and 8115 with normal blood pressure, stratified in four age groups: 20-29, 30-39, 40-49 and 50-59 years. Clinical evaluation included measures of heart rate (by pulse palpation), blood pressure (by mercury sphygmomanometer), total cholesterol, triglycerides, blood glucose and fibrinogen, and details of medical history and personal habits, with particular regard to smoking habits. Results Heart rate, which was significantly higher in hypertensive than in normotensive individuals, showed no significant change with age in the normotensive group, but a slight decline with increasing age in those with hypertension. In the normotensive group, heart rate was significantly higher in smokers than in non-smokers and ex-smokers, and showed no significant variation with increasing age, independently of smoking habits. Among those with hypertension, heart rate was not statistically different in smokers, non-smokers and ex-smokers, and showed a moderate decrease with age in non-smokers and ex-smokers, but did not change with age in smokers. Conclusions Both ageing and smoking habits have different effects on heart rate in normotensive and hypertensive individuals.

Fibrinogen levels in normotensive and hypertensive men: a cross-sectional study.

Background: The aim of this study was to compare plasma fibrinogen levels in hypertensive and normotensive men. Possible confounding factors, such as age, cholesterol levels, body-mass index and smoking habits were also to be considered. Methods: We studied 708 men with essential hypertension (according to the World Health Organizations criteria) and 944 with normal blood pressures, all of whom had similar lifestyles; the overall age range was 18–60 years. The clinical evaluation included measurements of blood pressure, heart rate, body weight and height as well as a medical examination and personal habits history. After an overnight fast, blood samples were taken in order to measure fibrinogen and total-cholesterol levels. Results: The mean fibrinogen level did not differ between the groups, although the distribution of the levels was different and was J-shaped in the hypertensive group. Plasma fibrinogen levels increased significantly with age in both groups. A significant positive correlation was found between fibrinogen and total-cholesterol levels, but not between fibrinogen and body-mass index or systolic or diastolic blood pressures. Cigarette smokers had significantly higher fibrinogen levels than non-smokers, irrespective of their blood pressure status; ex-smokers had intermediate values, suggesting a direct but reversible effect of tobacco. In cigarette smokers, fibrinogen levels increased with the number of cigarettes smoked, which is indicative of a dose-response relationship. Conclusion: This study confirms the strong association between fibrinogen levels and smoking and the weaker association with age and total-cholesterol levels. Mean fibrinogen level was not significantly related to blood pressure, although the distribution of fibrinogen levels appeared to be J-shaped in hypertensive men.